About Technology Issues FAQ

Links

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.